The ANXA5 Knockout A-549 Polyclonal Cells product provides a pool of CRISPR/Cas9-edited A-549 cells carrying targeted disruption of the ANXA5 gene. This polyclonal knockout population is designed for functional investigation of annexin A5 loss-of-function in a human lung adenocarcinoma background, without clonal selection. The cells serve as a versatile model for dissecting ANXA5-mediated processes in signal transduction, membrane biology, and disease-related pathways.
The parental A-549 cell line originates from a human Caucasian lung carcinoma and displays an adherent epithelial morphology with a KRAS gain-of-function mutation. These cells are widely employed as an in vitro model of alveolar type II epithelium, making them relevant to studies of pulmonary adenocarcinoma pathology, respiratory epithelium biology, and oncogenic Ras signaling. Their stable growth characteristics and defined genetic background support robust experimental reproducibility.
Annexin A5 is a calcium-dependent phosphatidylserine-binding protein that assembles into a two-dimensional crystalline lattice on exposed membrane phospholipids, thereby inhibiting coagulation and regulating apoptotic cell clearance. ANXA5 expression is governed by upstream factors including p53, glucocorticoids, TGFB1, and the vitamin D receptor. Downstream, it modulates phospholipase A2 activity, protein kinase C signaling, and coagulation factor assembly, while physically interacting with integrin beta 5, actin, and S100A10. Within the apoptosis pathway, ANXA5 acts in concert with caspase 3 to influence cell death and efferocytosis.
In A-549 cells, which harbor an oncogenic KRAS alteration, disruption of ANXA5 is predicted to perturb phosphatidylserine-dependent signaling networks, impair membrane repair responses, and potentially alter sensitivity to stress-induced apoptosis. Given the role of ANXA5 in anti-inflammatory processes and its interaction with cytoskeletal and integrin components, knockout in this lung adenocarcinoma model may reveal vulnerabilities in tumor cell adhesion, migration, or drug resistance, thereby providing insights into lung cancer progression pathways.
Investigators can employ this knockout model to explore ANXA5 function in lung cancer through assays such as Western blotting, RT-qPCR, and cell migration/invasion studies. For apoptosis and efferocytosis research, Annexin V-FITC staining and coagulation assays enable detailed analysis of phosphatidylserine exposure and anticoagulant activity. The cells are also suitable for drug screening campaigns targeting thrombosis and membrane dynamics investigations using immunofluorescence for phosphatidylserine localization. For additional technical specifications or to discuss custom applications, please contact Ascent Research.
